<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738840</url>
  </required_header>
  <id_info>
    <org_study_id>CRD_800</org_study_id>
    <nct_id>NCT02738840</nct_id>
  </id_info>
  <brief_title>A Post-Market Study Evaluating the Prodigy MRI and Proclaim Elite MR Conditional SCS Systems</brief_title>
  <acronym>SCS MRI PMCF</acronym>
  <official_title>A Post-Market Study Evaluating the Prodigy MRI and Proclaim Elite MR Conditional SCS Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post market study evaluating the safety of the Prodigy MRI and Proclaim Elite MR
      conditional SCS systems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed as an international, multicenter, prospective and single-arm
      design. The study will be conducted as a Post Market Clinical Follow Up (PMCF) study and the
      results will be submitted to the Notified Body: BSI Group (BSI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of the MRI scan-related adverse events</measure>
    <time_frame>1 month post MRI scan</time_frame>
    <description>The primary objective of the study is to confirm the safety of the Prodigy MRI and Proclaim Elite MR conditional SCS systems</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of successful device functionality checks</measure>
    <time_frame>1 month post MRI scan</time_frame>
    <description>The secondary objective is to confirm that the MRI scan does not affect the functionality of the Prodigy MRI or Proclaim Elite MR conditional SCS system</description>
  </secondary_outcome>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Chronic Pain</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI scan</intervention_name>
    <description>MRI scan</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population enrolled in this study will be comprised of male and female
        subjects. Subjects have to meet specific eligibility criteria in order to participate in
        the study. 49 subjects will be enrolled. Data from only 1 scan per subject will be
        collected in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been implanted with a Prodigy MRI or Proclaim Elite MR conditional SCS
             system

          -  Patient will receive an MRI scan in compliance with the IFU for the implanted MR
             conditional SCS system

          -  Patient is ≥ 18 years of age

          -  Patient must be willing and able to comply with study requirements

          -  Patient must indicate his/her understanding of the study and willingness to
             participate by signing an appropriate Informed Consent Form

        Exclusion Criteria:

          -  Patient has another implanted device (active or passive) that prohibits safe scanning

          -  Patient has previously experienced an MRI scan-related adverse event

          -  Patient is currently enrolled in another Abbott study that collects MRI safety data

          -  Patient is incapacitated, is unable to read or write, or is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Harbert</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Harbert</last_name>
    <email>nicole.harbert@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Gustorff, DEAA</last_name>
      <phone>+43149150</phone>
      <phone_ext>4001</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Herwig Kloimstein, MD</last_name>
      <phone>+43149150</phone>
      <phone_ext>4008</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St Augustinus Ziekenhuis</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Vanhavenbergh, MD</last_name>
      <email>T.vanhavenbergh@gza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universität Düsseldorf, Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Vesper, MD</last_name>
      <email>jan.vesper@med.uni-duesseldorf.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Gera -Zentrum für interdisziplinäre Schmerztherapie, Gera</name>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kretzschmar, MD</last_name>
      <email>Michael.Kretzschmar@wkg.srh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico S.S. Annunziata</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amedeo Constantini, MD</last_name>
      <email>amedeocostantini@tiscali.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>l'Azienda Ospedaliero- Universitaria Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliano Carolis, MD</last_name>
      <email>giulianodecarolis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Santa Maria Delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Marquez, MD</last_name>
      <email>jaca5@arrakis.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seacroft Hospital</name>
      <address>
        <city>Leeds</city>
        <state>Ykshre</state>
        <zip>LS14 6UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganesan Baranidharan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

